Unlocking gene control mechanisms to develop small molecule therapies


Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes.


Year Invested: 2016
Location: Cambridge, MA
Visit: www.fulcrumtx.com

Recent News

September 5, 2018
Fulcrum Therapeutics Announces $80 Million Series B Financing

August 14, 2018
Fulcrum Therapeutics Promotes Diego Cadavid, M.D., to Senior Vice President, Clinical Development

June 27, 2018
Fulcrum Therapeutics Strengthens Board of Directors with Appointment of Kate Haviland

Read More News

Associated Team Members

Mark Levin
Partner

Philip Reilly, M.D., J.D.
Venture Partner

Walter Kowtoniuk, Ph.D.
Principal